Abiopharma

🔍 Chan Phillip P. (Director)

Company: Cytosorbents Corp (CTSO)

Report Date: 2026-06-12

Detailed Transactions and Holdings:

• Acquired 251,136 shares of Common Stock at $0.4 per share (Direct)
  Date: 2026-06-12 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,734,099.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 10,333 shares of Common Stock at $0.43 per share (Direct)
  Date: 2026-06-15 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,744,432.00 | transaction_form_type: 4 | Footnotes: F4, F2

Footnotes:

• F1: The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.3885 to $0.40, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.
• F2: Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
• F3: (continued from footnote 2) (iii) 105,600 RSUs granted on August 8, 2025, which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iv) 1,422,832 shares of Common Stock owned by the Reporting Person.
• F4: The transaction reported on this Form 4 reflects an open market purchase made by the reporting person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4307 to $0.4388, inclusive.